Pfizer Persists: Big Opportunities And Challenges In Vaccines

The big pharma has two vaccines that have progressed to late-stage development, one for Clostridium difficile infection and the other for Staph aureus. Both represent big commercial opportunities, but bringing a new vaccine to market is a slow process.